Literature DB >> 31211368

Natural history of spinal cord arteriovenous shunts: an observational study.

Jia-Xing Yu1,2, Tao Hong1,2, Timo Krings3, Chuan He1,2, Ming Ye1,2, Li-Yong Sun1,2, Xiao-Dong Zhai1,2, Si-Shi Xiang1,2, Yong-Jie Ma1,2, Li-Song Bian4, Jian Ren1,2, Peng-Yu Tao1,2, Jing-Wei Li1,2, Fan Yang5, Gui-Lin Li1,2, Feng Ling1,2, Hong-Qi Zhang1,2.   

Abstract

The natural history of intradural spinal cord arteriovenous shunts is unknown. We performed an observational study in a consecutive patient cohort with symptomatic intradural spinal cord arteriovenous shunts who were admitted to three institutes to investigate the clinical course of this complex disease, which would provide valuable evidence to inform clinical decision-making. The clinical course of patients with symptomatic intradural spinal cord arteriovenous shunts from initial presentation to occurrence of clinical deterioration, initiation of treatment, or last follow-up was analysed. Patients with at least 1 month of observation were included in this study. Clinical onset and deterioration patterns were divided into acute and gradual. Annual and cumulative rates of clinical deterioration as well as their risk factors were analysed using Kaplan-Meier life table analysis and Cox proportional hazards model. To assess risks and benefits of treatment, post-treatment clinical courses were further assessed. Four hundred and sixty-six patients with a mean observational period of 36.9 ± 58.8 months were included; 56.7% of patients presented with acute onset, of whom 77.3% experienced spontaneous recovery. Age of onset older than 28 years, initial modified Aminoff and Logue scale of >3, mid-thoracic lesions and non-ventral lesions were independent predictors of failure for spontaneous recovery. The annual risk of general, acute and gradual clinical deterioration after onset was 30.7%, 9.9% and 17.7%, respectively. Risk of deterioration was highest in the early period after initial onset. Acute onset was the only independent risk factor [hazard ratio 1.957 (95% confidence interval, CI 1.324-2.894); P = 0.0008] of acute deterioration and gradual onset was the strongest predictor [hazard ratio 2.350 (95% CI 1.711-3.229); P < 0.0001] of the gradual deterioration among all the stratifying factors. After invasive treatment, complete obliteration was achieved in 37.9% of patients (138 of 364) and improved or stable clinical status was noted in 80.8% of patients. Forty-two patients (11.5%) experienced permanent complications. Overall post-treatment deterioration rate was 8.4%/year, and 5.3%/year if permanent complications were excluded. The natural history of symptomatic spinal cord arteriovenous shunts is poor, especially in the early period after onset, and early intervention is thus recommended. Initial onset pattern significantly affects the natural history of the lesion, which prompts a differentiated treatment strategy.
© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  arteriovenous shunt; natural history; perimedullary arteriovenous fistula; spinal arteriovenous malformation; spinal metameric arteriovenous malformation

Mesh:

Year:  2019        PMID: 31211368     DOI: 10.1093/brain/awz153

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  2 in total

1.  Novel classification for simple peripheral arteriovenous malformations based on anatomic localization: Prevalence data from the tertiary referral center in China.

Authors:  Yuchen Shen; Zhenfeng Wang; Xitao Yang; Lianzhou Zheng; Mingzhe Wen; Yifeng Han; Xiao Li; Liming Zhang; Jingbing Wang; Jianxiong You; Chunyu Jiang; Lixin Su; Xindong Fan; Deming Wang
Journal:  Front Cardiovasc Med       Date:  2022-07-22

2.  Diagnostic accuracy of three-dimensional-rotational angiography and heavily T2-weighted volumetric magnetic resonance fusion imaging for the diagnosis of spinal arteriovenous shunts.

Authors:  Bikei Ryu; Shinsuke Sato; Masayuki Takase; Tatsuki Mochizuki; Shogo Shima; Tatsuya Inoue; Yoshikazu Okada; Yasunari Niimi
Journal:  J Neurointerv Surg       Date:  2021-03-04       Impact factor: 5.836

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.